CASI Pharmaceuticals Files 6-K, Incorporates Exhibits
Ticker: CASIF · Form: 6-K · Filed: Aug 29, 2025 · CIK: 1962738
| Field | Detail |
|---|---|
| Company | Casi Pharmaceuticals, INC. (CASIF) |
| Form Type | 6-K |
| Filed Date | Aug 29, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, registration-statement
Related Tickers: CASI
TL;DR
CASI Pharma filed a 6-K on 8/29/25, incorporating exhibits into its F-3 registration statements.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on August 29, 2025, to incorporate by reference information from Exhibits 99.1 into its existing Registration Statements on Form F-3 (File No. 333-283998 and No. 3). This filing is for the month of August 2025 and pertains to its status as a foreign private issuer.
Why It Matters
This filing indicates ongoing regulatory compliance and updates to the company's registration statements, which are crucial for potential future capital raises or ongoing reporting requirements.
Risk Assessment
Risk Level: low — This is a routine filing to incorporate existing documents into registration statements, not indicating new material events or financial distress.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Filer of the Form 6-K
- August 29, 2025 (date) — Filing date of the Form 6-K
- Form F-3 (document) — Registration statement type referenced
- File No. 333-283998 (document) — Specific registration statement file number
FAQ
What is the purpose of this Form 6-K filing?
The purpose is to report information for the month of August 2025 and to incorporate by reference Exhibits 99.1 into the Company's Registration Statements on Form F-3.
What is the filing date of this report?
The filing date is August 29, 2025.
What are the company's principal executive offices?
The company's principal executive offices are located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
Does CASI Pharmaceuticals file annual reports under Form 20-F or 40-F?
The company indicates it files annual reports under Form 20-F.
What is the SEC file number for CASI Pharmaceuticals?
The SEC file number for CASI Pharmaceuticals is 001-41666.
Filing Stats: 234 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2025-08-29 16:30:23
Filing Documents
- tm2524634d1_6k.htm (6-K) — 11KB
- tm2524634d1_ex99-1.htm (EX-99.1) — 89KB
- tm2524634d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-25-085718.txt ( ) — 107KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ David Cory Name: David Cory Title: CEO Date: August 29, 2025